Rabin Medical Center
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 1936-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://rabin-medical.org
Clinical Trials
388
Active:4
Completed:109
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:19
Phase 2:30
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (294 trials with phase data)• Click on a phase to view related trials
Not Applicable
172 (58.5%)Phase 4
46 (15.6%)Phase 2
30 (10.2%)Phase 3
25 (8.5%)Phase 1
19 (6.5%)Early Phase 1
2 (0.7%)Assessing the Safety, Performance, and User Experience of the Tandem Mobi Automated Insulin Delivery System Among Young Competitive Athletes in Real-world Settings.
Not Applicable
Not yet recruiting
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT06979635
- Locations
- 🇮🇱
Schneider Children's Medical Center of Israel, Petach-Tikva, Israel
Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections
Not Applicable
Recruiting
- Conditions
- Type 1 DiabetesType 2 Diabetes
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT06966427
- Locations
- 🇮🇱
Schneider Children Medical Center of Israel, Petach Tikva, Israel
🇸🇮University Medical Center of Ljubljana, Ljubljana, Slovenia
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06951399
- Locations
- 🇮🇱
Davidoff Comprehensive Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumors Refractory to Standard Therapy
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06940349
- Locations
- 🇮🇱
Davidoff cancer center, RMC, Petah Tikva, Israel
Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients
Phase 1
Not yet recruiting
- Conditions
- Pruritus
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06931119
- Prev
- 1
- 2
- 3
- 4
- 5
- 78
- Next
News
CBD Shows Promise in Curbing SARS-CoV-2 Replication, Clinical Trials Needed
Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials.